Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort studyGerardo Priotto
Epicentre, 75011 Paris, France
BMJ 336:705-8. 2008
..To assess the safety and effectiveness of eflornithine as first line treatment for human African trypanosomiasis...
Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in CongoGerardo Priotto
Epicentre, Paris, France
Clin Infect Dis 45:1435-42. 2007
..We compared the efficacy and safety of the nifurtimox-eflornithine drug combination with the standard eflornithine regimen for the treatment of second-stage disease...
- Artesunate and sulfadoxine-pyrimethamine combinations for the treatment of uncomplicated Plasmodium falciparum malaria in Uganda: a randomized, double-blind, placebo-controlled trial
Gerardo Priotto
Epicentre, 8 rue Saint Sabin, 75011 Paris, France
Trans R Soc Trop Med Hyg 97:325-30. 2003
..Treatment efficacy improved with SPAS3 but the cure rate at day 28 was modest. The combinations were well tolerated and safe. In areas where SP resistance is prevalent other combinations should be considered...
Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trialGerardo Priotto
Epicentre, Paris, France
Lancet 374:56-64. 2009
..We assessed the efficacy and safety of nifurtimox-eflornithine combination therapy (NECT) for second-stage disease compared with the standard eflornithine regimen...
- Antimalarial efficacy of sulfadoxine-pyrimethamine, amodiaquine and a combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi Bugyo, western Uganda
Francesco Checchi
Epicentre, Paris, France
Trop Med Int Health 9:445-50. 2004
..Our study also confirms previous findings that resistance is considerably underestimated by 14-day follow-ups. Antimalarial policy decisions should therefore be based on 28-day studies, with PCR adjustment to distinguish re-infections...
- Nifurtimox plus Eflornithine for late-stage sleeping sickness in Uganda: a case series
Francesco Checchi
Epicentre, Paris, France
PLoS Negl Trop Dis 1:e64. 2007
....
- Early prediction of treatment efficacy in second-stage gambiense human African trypanosomiasis
Gerardo Priotto
Epicentre, Paris, France
PLoS Negl Trop Dis 6:e1662. 2012
..We analyzed individual patient data from 12 programs conducted by Médecins Sans Frontières in Uganda, Sudan, Angola, Central African Republic, Republic of Congo and Democratic Republic of Congo searching for early efficacy indicators...
- Molecular genotyping in a malaria treatment trial in Uganda - unexpected high rate of new infections within 2 weeks after treatment
Kefas Mugittu
Ifakara Health Research and Development Centre, Ifakara, Tanzania
Trop Med Int Health 12:219-23. 2007
..2%)] and 14 [24/51 (47.1%)]. These results impact significantly on resistance monitoring and point to the value of genotyping all recurrent infections in antimalarial trials...
- Malaria epidemics and interventions, Kenya, Burundi, southern Sudan, and Ethiopia, 1999-2004
Francesco Checchi
Department of Infectious and Tropical Disease, London School of Hygiene and Tropical Medicine, London, United Kingdom
Emerg Infect Dis 12:1477-85. 2006
....
- The outbreak and control of Ebola viral haemorrhagic fever in a Ugandan medical school
Medard Bitekyerezo
Mbarara University Teaching Hospital, Uganda
Trop Doct 32:10-5. 2002
..The implications for similar institutions in East Africa are discussed...
